Nothing said here yet.
to join the conversation.
| Wong-Sarad GracePrincipal Accounting Officer | Sell | 3,625 | $9.1K | Fri, Sep 4 |
| Rosenthal ArnonChief Executive Officer | Sell | 72,606 | $193.5K | Thu, Sep 3 |
| Berkley Neil LindsayCFO & Chief Business Officer | Sell | 29,251 | $77.9K | Thu, Sep 3 |
| Wong-Sarad GracePrincipal Accounting Officer | Sell | 5,165 | $13.8K | Thu, Sep 3 |
| Wong-Sarad GracePrincipal Accounting Officer | Sell | 656 | $1.8K | Wed, Sep 2 |
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investing.com -- Alector shares surged about 13% in premarket trading Friday following the company’s announcement of a $75 million stock offering priced at a premium to the previous day’s close.
Alector’s internal fair value estimate has shifted from US$3.10 to US$3.90 per share, which places it in the lower half of the current analyst price target range.
Alector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA programs targeting tau and alpha-synuclein.
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.
Alector will receive $100 million upfront and could earn up to $1. 17 billion in additional milestones while Genentech assumes responsibility for developing and commercializing AL050 globally.